Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
作者信息
Maiorano Brigida Anna, Ciardiello Davide, Maiello Evaristo, Roviello Giandomenico
机构信息
Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.
出版信息
JAMA Netw Open. 2023 May 1;6(5):e2314144. doi: 10.1001/jamanetworkopen.2023.14144.
Abstract
摘要
相似文献
1
Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
JAMA Netw Open. 2023 May 1;6(5):e2314144. doi: 10.1001/jamanetworkopen.2023.14144.
2
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
Clin Genitourin Cancer. 2019 Jun;17(3):169-176.e1. doi: 10.1016/j.clgc.2019.01.014. Epub 2019 Feb 4.
3
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.
4
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Cancer Treat Rev. 2021 Sep;99:102242. doi: 10.1016/j.ctrv.2021.102242. Epub 2021 Jun 12.
5
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Cancer Sci. 2020 Mar;111(3):907-923. doi: 10.1111/cas.14294. Epub 2020 Feb 5.
6
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7.
7
Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression.
Med Sci (Basel). 2024 Sep 13;12(3):48. doi: 10.3390/medsci12030048.
8
Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Anticancer Res. 2019 Sep;39(9):4737-4742. doi: 10.21873/anticanres.13656.
9
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int. 2020 Jul;126(1):73-82. doi: 10.1111/bju.15058. Epub 2020 Apr 24.
10
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
引用本文的文献
1
Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series.
BMC Cancer. 2024 Jul 5;24(1):804. doi: 10.1186/s12885-024-12572-4.
2
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.
Nat Rev Clin Oncol. 2024 Jun;21(6):468-482. doi: 10.1038/s41571-024-00886-y. Epub 2024 Apr 10.
3
First-line ICIs in renal cell carcinoma.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2225386. doi: 10.1080/21645515.2023.2225386. Epub 2023 Jul 3.
本文引用的文献
1
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10.
2
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9.
3
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Oncol Rev. 2020 Jul 21;14(2):490. doi: 10.4081/oncol.2020.490. eCollection 2020 Jul 6.
4
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
Zotero 插件